Third-Party Manufacturer Inspection Nets Checkpoint Therapeutics a CRL

Checkpoint Therapeutics announced that the FDA has issued a complete response letter (CRL) for its cosibelimab BLA based on an inspection of the company’s third-party manufacturer, with no issues cited on the approvability of the drug itself.
Source: Drug Industry Daily